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Polybrominated diphenyl ethers (PBDEs) are 
flame retardants commonly used in an array 
of products, including construction materials, 
electronics, furnishings, plastics, poly  urethane 
foams, and textiles (Brown et al. 2004). PBDEs 
are found in various environ  mental media (Bi 
et al. 2006; Guan et al. 2009; Thomsen et al. 
2010) and are health hazards. They are toxic, 
persistent, and bioaccumulative and could 
induce endocrine-disrupting activity (Darnerud 
et al. 2001; Hamers et al. 2006, 2008; 
Richardson et al. 2008). Thus, the Stockholm 
Convention approved the elimination of their 
industrial production and use. Nevertheless, 
commercial PBDE mixtures are used without 
regulation in most Asian countries (Tan 
et al. 2007). Deca-PBDE is the only PBDE 
technical mixture currently produced in large 
quantities worldwide, a major component of 
which is PBDE congener 209 (La Guardia 
et al. 2006). Evidence indicates that PBDEs 
can cause neuro  behavioral deficits and 
possibly cause cancer in experi  mental animals 
(McDonald 2002).
Molecularly, PBDEs elicit thyroxine-like 
and estrogen-like activity in vitro (Meerts 
et al. 2000). Barber et al. (2006) showed that 
low doses of PBDE (10–12 to 10–9 M) induce 
growth kinetics and micro  nucleus forma-
tion in MCF-7 breast cancer cells. Llabjani 
et al. (2010, 2011) and Ukpebor et al. (2011) 
also found that low doses of PBDE induce 
MCF-7 cell proliferation. Mercado-Feliciano 
and Bigsby (2008) showed that the PBDE 
mixture DE-71 increases MCF-7 cell prolif-
eration, which was prevented by anti  estrogen 
treatment. PBDEs affect both male and female 
reproductive systems in vivo (Ceccatelli et al. 
2006; Kuriyama et al. 2005; Lilienthal et al. 
2006; Stoker et al. 2004; Talsness et al. 2005; 
Tseng et al. 2006). Metabolically, PBDE con-
geners PBDE-47, PBDE-85, and PBDE-99 
are selectively taken up and retained in the 
liver, adrenal cortex, and ovaries after PBDE 
exposure in adult C57BL mice (Darnerud and 
Risberg 2006). Talsness et al. (2008) demon-
strated that exposure to low concentrations 
of PBDE-47 in utero and during lactation 
decrease the offspring’s ovarian weight and size 
of tertiary follicles. These studies indicate that 
PBDEs may significantly affect the reproduc-
tive system and be responsible for increasing 
cancer incidence in the mammary glands, 
uterus, and ovary. Therefore, in the present 
study we investigated the effects of PBDEs on 
breast, cervical, and ovarian cancer cell lines 
using normal Chinese hamster ovary (CHO) 
cells as the control. We also investigated the 
effects of PBDE-209 on regulation of tamox-
ifen-induced apoptosis in breast cancer cells 
because PBDE has been shown to disrupt hor-
mones, including estrogen. We then exam-
ined the under  lying molecu  lar mechanisms by 
which PBDEs induce protein alterations.
Materials and Methods
Cell lines and culture. The MCF-7 human 
breast cancer cell line, the multidrug-resistant 
MCF-7 cell line MCF-7/ADR, and OVCAR-3 
human ovarian cancer cell line were a generous 
gift from W. Huang (Sun Yat-Sen University, 
Guangzhou, China). We obtained the HeLa 
human cervical cancer cell line and CHO 
(Chinese hamster ovary) cell line from the 
Experimental Animal Center at Sun Yat-Sen 
University. 
MCF-7 and MCF-7/ADR cells were 
maintained  in  RPMI-1640  medium, 
OVCAR-3 and HeLa cells were cultured in 
HEPES-buffered Dulbecco’s modified Eagle’s 
medium (H-DMEM), and CHO cells were 
maintained in DMEM-F12 medium. All 
media were supplemented with 10% fetal 
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Ba c k g r o u n d: Polybrominated diphenyl ethers (PBDEs), commonly used in building materials, 
electronics, plastics, polyurethane foams, and textiles, are health hazards found in the environment.
oB j e c t i v e: In this study we investigated the effects of PBDE‑209, a deca‑PBDE, on the regulation 
of growth and apoptosis of breast, ovarian, and cervical cancer cells as well as the under  lying protein 
alterations. 
Me t h o d s : We used MCF‑7 and MCF‑7/ADR (multidrug‑resistant MCF‑7) breast cancer cell 
lines, the HeLa cervical cancer cell line, the OVCAR‑3 ovarian cancer cell line, and the normal 
CHO (Chinese hamster ovary) cell line to assess the effects of PBDE‑209 using cell viability, 
immuno  fluorescence, and flow cytometric assays. Western blot assays were used to detect changes 
in protein expression. To assess the effects of PBDE‑209 on apoptosis, we used the protein kinase 
Cα (PKCα) inhibitor Gö 6976, the extracellular signal‑regulated kinase (ERK) inhibitor PD98059, 
and tamoxifen. 
re s u l t s: Our data indicate that PBDE‑209 increased viability and proliferation of the tumor 
cell lines and in CHO cells in a dose‑ and time‑dependent manner. PBDE‑209 also altered cell 
cycle distribution by inducing the S phase or G2/M phase. Furthermore, PBDE‑209 partially sup‑
pressed tamoxifen‑induced cell apoptosis in the breast cancer cell lines (MCF‑7 and MCF‑7/ADR) 
but suppressed Gö 6976‑ and PD98059‑induced apoptosis in all cell lines. At the molecular level, 
PBDE‑209 enhanced PKCα and ERK1/2 phosphorylation in the cell lines. 
co n c l u s i o n s: Our data demonstrate that PBDE‑209 is able to promote prolifera  tion of various 
cancer cells from the female reproductive system and normal ovarian CHO cells. Furthermore, it 
reduced tamoxifen, PKCα, and ERK inhibition‑induced apoptosis. Finally, PBDE‑209 up‑regulated 
phosphorylation of PKCα and ERK1/2 proteins in tumor cells and in CHO cells. 
key w o r d s : cell proliferation, ERK1/2, female reproductive cancer, PBDE‑209, PKCα. Environ 
Health Perspect 120:541–546 (2012).  http://dx.doi.org/10.1289/ehp.1104051 [Online 6 January 
2012]Li et al.
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bovine serum (FBS), 100 U/mL penicillin, and 
100 μg/mL streptomycin (all from Gibco BRL, 
Grand Island, NY, USA). Cells were cultured 
at 37°C in a humidified atmosphere of 95% 
air and 5% CO2. Third- or fourth-passage 
cells were used for our experiments. MCF-7 
and MCF-7/ADR cells were grown in phenol 
red–free RPMI-1640 supplemented with 10% 
DCC-FBS (dextran-coated charcoal–stripped 
FBS; Sigma Chemical Co., St. Louis, MO, 
USA) according to Migliaccio et al. (1993). 
After 24 hr culture, cells were starved overnight 
with phenol red–free RPMI-1640 containing 
1% DCC-FBS (for breast cancer cells), 
H-DMEM (for OVCAR-3 and HeLa cells), or 
DMEM-F12 with 1% FBS (for CHO cells). 
Cells were treated with PBDE-209, tamoxifen, 
the protein kinase Cα (PKCα) inhibitor 
Gö 6976, or the extra  cellular signal-regulated 
kinase (ERK) inhibitor PD98059 (all from 
Sigma) added into the culture medium as 
described for specific experiments. 
Cell viability by MTT (methylthiazolyl­
diphenyl tetra  zolium bromide) assay. We 
used the MTT assay to assess cell viability 
(Mosmann 1983). Cells were seeded in 96-well 
plates at approximately 103–104 cells/well   
in 200 μL medium for 24 hr, followed by star-
vation for another 24 hr. The cells were then 
divided into four groups in triplicate: a) blank 
control; b) dimethyl sulfoxide (DMSO) vehicle 
control; c) PBDE-209 at a final PBDE-209 
concentration of 5, 15, 25, 50, or 100 nM; and 
d) 10% FBS positive control (cells cultured only 
with medium plus 10% FBS). The percent cell 
viability was calculated as (A490 of treated cells 
– A490 of blank control) ÷ (A490 of negative 
control – A490 of blank control) × 100%, as 
described previously (Shen et al. 1995).
Cell proliferation by immuno  fluorescent 
staining of Ki67. Cells were grown and treated 
as above and then subjected to immuno-
fluorescent staining of Ki67, a marker for cell 
proliferation. Briefly, the cells were fixed in 
4% paraformaldehyde, treated with 0.01% 
Triton X-100 for 30 min, incubated with 5% 
bovine serum albumin in phosphate-buffered 
saline (PBS) for 30 min and then incubated 
with the Ki67 antibody (1:200; Lab Vision, 
Fremont, CA, USA) overnight at 4°C. The next 
day, cells were washed with PBS and incubated 
with Cy3-labeled goat anti-rabbit secondary 
antibody (Sigma) at room temperature for 2 hr 
and with 0.001% DAPI (4´,6-diamidino-2-
phenylindole)/PBS for 15 min. The cells were 
submerged, resuspended in glycerol/PBS, 
reviewed, and scored using an inverted fluores-
cence micro  scope (Leica, Wetzlar, Germany). 
Images were recorded and merged using Adobe 
Photoshop CS software (Adobe Systems Inc., 
San Jose, CA, USA).
Flow cytometry assay. We measured cell 
cycle distribution and apoptosis using pro-
pidium iodide staining and a flow cytometer 
(model FC500; Beckman-Coulter, Brea, CA, 
USA) as described previously by Mandil et al. 
(2001). Briefly, tumor cells were grown and 
treated with 0–100 nM PBDE-209 for 72 hr. 
Breast cancer cells (MCF-7 and MCF-7/ADR) 
were also co-treated with 5 μM tamoxi  fen in 
the presence of 50 or 100 nM PBDE-209 for 
72 hr. In addition, the cells were pretreated 
independently with 0.1 μM Gö 6976 or 20 μM 
PD98059 for 30 min before treatment with 0, 
25, 50, or 100 nM PBDE-209 for 72 hr. Each 
experiment was repeated in triplicate.
Protein extraction and Western blotting. 
The cells were lysed according to a proto-
col described previously (Li et al. 1999). We 
obtained rabbit polyclonal antibodies against 
phosphorylated PKCα, phosphorylated ERK, 
and β-actin from Cell Signaling Technology 
(Beverly, MA, USA); horseradish peroxidase–
conjugated rabbit or secondary anti  bodies 
from QED Biovision, Inc. (Hercules, CA, 
USA); and enhanced chemiluminescence 
detection equipment from GE Healthcare 
(Chalfont St. Giles, UK).
Statistical analysis. Statistical analysis was 
performed with the SPSS software (version 11.5; 
SPSS, Chicago, IL, USA). Data are expressed as 
mean ± SD. We used independent-samples 
t-test and analyses of variance to assess the 
statistical significance of the samples. The 
difference is considered statistically signifi  cant 
at p < 0.05.
Results
PBDE­209 induced phenotypic changes. To 
assess the effects of PBDEs on different tumor 
cell lines, we treated cells with up to 100 nM 
PBDE-209 for 72 hr and evaluated if there 
were changes in their morphology. We found 
that, with increasing PBDE-209 dose, cells 
grew more rapidly and were closer to each 
other; thus the cell gaps were decreased com-
pared with control cells, which was more obvi-
ous in MCF-7 cells than in MCF-7/ADR cells 
and more obvious in OVCAR-3 cells than in 
CHO cells. The cell viability assay showed that 
the absorption reading of PBDE-209–treated 
cells increased gradually as the PBDE-209 
dose increased (Figure 1). For example, 
MCF-7 cells with 25 nM PBDE-209 treat-
ment had a proliferative rate 1.22 times higher 
than that of control cells, and the prolifera-
tive rate in MCF-7 cells treated with 100 nM 
PBDE-209 was 1.85 times higher than that 
of control cells. In contrast, MCF-7/ADR 
cells were less sensitive to PBDE-209 than 
were MCF-7 cells: the proliferative rate of 
cells treated with 50 nM PBDE-209 was only 
1.25 times higher than that of control cells and 
1.32 times higher in cells treated with 100 nM 
PBDE-209 (p < 0.05; Figure 1). Moreover, 
OVCAR-3 cells responded to PBDE-209 
more strongly than did normal ovarian CHO 
cells: Increasing the PBDE-209 dose to 
100 nM led to a proliferative rate of 1.86 in 
OVCAR-3 cells, compared with about 1.50 in 
CHO cells (p < 0.05). However, the response 
of HeLa cells to PBDE-209 was simi  lar to 
that of CHO cells. These data indicate that 
response of these tumor cells to PBDE-209 
treatment was dose and cell line dependent.
Figure 1. Cell viability in MCF‑7 and MCF‑7/ADR cells (A) and in OVCAR‑3, HeLa, and CHO cells (B) determined by MTT assay. Cells were grown, starved overnight 
without serum, treated with different doses of PBDE‑209 for 72 hr in medium containing 1% serum, and then subjected to MTT assay. Cells treated with 0.1% DMSO 
were used as the vehicle control (VC), and 10% FBS‑treated cells were used as the positive control (PC). The experiments were performed three times. Values 
shown are mean ± SD. 
*p < 0.05 versus VC. #p < 0.05 versus MCF‑7/ADR cells (A) or versus CHO cells (B) in the same treatment group. 
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We also determined the effects of 
PBDE-209 on induction of tumor cell pro-
liferation using Ki67 immuno  staining. The 
data showed that after PBDE-209 treatment 
for 72 hr, the number of Ki67-positive cells 
increased and the intensity of Ki67 expres-
sion was stronger compared with control cells 
without PBDE-209 treatment (Figure 2).
PBDE­209 induced cell cycle alterations. 
Khan and Dipple (2000) showed that anti-
benzo[a]pyrene antibody could induce evasion 
of G1 arrest to promote tumori  genicity, so we 
performed flow cytometry to detect the effects 
of PBDE-209 on cell cycle alteration in these 
tumor cell lines. To our surprise, PBDE-209 
decreased the percentage of cells in the G0/G1 
phase after 72 hr treatment but elevated the 
percentage of cells in the S phase, except for 
OVCAR-3 cells, which showed an increase 
in the G2/M phase (Figure 3). Data indicate 
that PBDE-209 increased the prolifera  tion 
index [PI; PI = (S + G2M) ÷ (G0/G1 + G2M)] 
after 72 hr of treatment (p < 0.05; Figure 3). 
The percentage of G0/G1 phase cells in 
the MCF-7/ADR cell was only 50–60%, 
and the percentage of S phase cells reached 
> 37% (Figure 3). Although the PI of the 
PBDE-209 test group was higher than that 
of control cells, the difference was significant 
only in cells treated with 100 nM PBDE-209 
(Figure 3).
PBDE­209 partially suppressed tamoxifen­ 
induced apoptosis in breast cancer cells. We 
examined the effects of PBDE-209 on 
regulation of tamoxifen-induced apoptosis 
in breast cancer cells because PBDE has 
been shown to disrupt hormones, including 
estrogen. We also examined expression of 
estrogen receptor α (ERα) and ERβ in breast 
cancer cells using immuno  fluorescence, 
Western blot, and reverse-transcriptase 
polymerase chain reaction (RT-PCR), as 
described in Supplemental Material (http://
dx.doi.org/10.1289/ehp.1104051). ERα and 
ERβ were expressed in MCF-7 cells but not in 
MCF-7/ADR cells (see Supplemental Material, 
Figures 1 and 2), which confirmed data from a 
previous study (Monje and Boland 2002). 
We also assessed the apoptosis ratio by flow 
cytometry in MCF-7 cells and MCF-7/ADR   
cells after treatment with 5 μM tamoxi-
fen in the presence of 50 nM or 100 nM 
PBDE-209. Figure 4 shows that the apoptosis 
rate in breast cancer cells exposed to 100 nM 
PBDE-209 alone was lower than that in con-
trol cells. Moreover, PBDE-209 was able 
to reduce tamoxifen-induced apoptosis in 
both MCF-7 cells and MCF-7/ADR cells. 
In MCF-7 cells the apoptosis rate decreased 
from 23.8% in the tamoxi  fen group to 19.7% 
in the tamoxi  fen plus 50 nM PBDE-209 
group and to 15.4% in the tamoxifen plus 
100 nM PBDE-209 group (Figure 4A). In   
MCF-7/ADR cells the apoptosis rate 
decreased from 8.4% to 5.0% and to 3.5%, 
respectively, in the three groups (Figure 4B). 
It is clear that treatment with 100 nM 
PBDE-209 suppressed tamoxifen-induced 
apoptosis in breast cancer cells (p < 0.05).
PBDE­209 induced PKCα and ERK1/2 
phosphorylation. Our data clearly demon-
strate that PBDE-209 leads to changes in cell 
prolifera  tion, cell cycle, and apoptosis. We 
therefore investigated the under  lying mecha-
nism by which PBDE-209 alters protein 
expression. Activation of PKCα and ERK 
proteins plays a role in cell prolifera  tion. In 
dose-dependent experiments, we observed that 
after 15 min of treatment with PBDE-209, 
PKCα phosphorylation was increased in all 
five cell lines and peaked at a dose of 50 nM 
or 100 nM, whereas ERK phosphorylation 
reached a maxi  mum level at 25 nM but 
remained high up to 100 nM PBDE-209 
(Figure 5A). For time-dependent experi-
ments in which cells were treated with 50 nM 
PBDE-209 for up to 120 min (Figure 5B), 
PKCα phosphorylation was apparent after 
15 min of treatment and reached a maximum at 
60 or 120 min, except for MCF-7 cells, which 
reached a maxi  mum at 15 min. Furthermore, 
PBDE-209-induced ERK1/2 phosphorylation 
peaked at 15 min in MCF-7, MCF-7/ADR, 
and OVCAR-3 cells and was maintained up 
to 120 min in MCF-7 and MCF-7/ADR cells 
and up to 60 min in OVCAR-3 cells. In HeLa 
cells, ERK was activated after 15 min exposure 
to PBDE-209 and then gradually rose to maxi-
mal levels at 120 min, whereas in CHO cells, 
ERK phosphoryla  tion reached a peak after 1 hr 
of treatment (Figure 5B).
Effects of PBDE­209 on regulation of 
Gö 6976 and PD98059­induced apoptosis. 
We investigated the effects of PBDE-209 
Figure 2. Detection of Ki67 expression in MCF‑7 and MCF‑7/ADR cells (A) and in OVCAR‑3, HeLa, and 
CHO cells (B) by immuno  fluorescence. Cells were grown, starved overnight without serum, treated with 
different doses of PBDE‑209 for 72 hr in medium containing 1% serum, and then subjected to immuno‑
fluorescence analysis of Ki67 expression. Cells treated with 0.1% DMSO were used as vehicle control 
(VC). The experiments were performed three times. Ki67 positivity is presented as the ratio of Ki67‑positive 
cells to the number of all cells in that cell line; data shown are mean ± SD. 
*p < 0.05 versus VC. **p < 0.01 versus VC. #p < 0.05 versus MCF‑7/ADR cells (A) or versus CHO cells (B) in the same treatment 
group. 
120
100
80
60
40
20
0
120
100
80
60
40
20
0
K
i
6
7
 
p
o
s
i
t
i
v
e
 
(
%
)
K
i
6
7
 
p
o
s
i
t
i
v
e
 
(
%
)
VC 25  50 
PBDE-209 (nM) PBDE-209 (nM)
100  25  50  100  VC
*
*
* *
*
**
**
*#
*# *#
*#
MCF-7
MCF-7/ADR
OVCAR-3
CHO
HeLa
Figure 3. Cell cycle profile determined by flow cytometry. Cells treated with 0.1% DMSO were used as 
vehicle control (VC; 0 nM PBDE‑209). The experiments were performed three times. Data shown are the 
percentage of cells at that phase of the cell cycle (mean ± SD). 
*p < 0.05 versus 0 nM PBDE‑209. 
02 55 0100
* *
* * * * * *
*
*
*
* *
* * *
* *
* *
* *
* *
*
* *
* *
*
*
*
G0/G1 G2/M
G0/G1 G2/M
G0/G1 G2/M
G0/G1 G2/M
G0/G1 G2/M
PI S PI S
02 55 0100 02 55 0100 02 55 0100 02 55 0100 02 55 0100 02 55 01 00 02 550100
100
80
60
40
20
0
100
80
60
40
20
0
100
80
60
40
20
0
100
80
60
40
20
0
100
80
60
40
20
0
PBDE-209 (nM) PBDE-209 (nM)
PBDE-209 (nM)
PBDE-209 (nM)
PBDE-209 (nM) 02 55 0 100
PI S PI S
02 55 0100 02 55 0100 02 55 0100 02 55 0100 02 55 0100 02 55 0100 02 55 0100
02 55 01 00
PI S
02 55 0100 02 55 0100 02 55 0100
MCF-7
OVCAR-3 CHO
HeLa
MCF-7/ADRLi et al.
544  v o l u m e  120 | n u m b e r 4 | April 2012  •  Environmental Health Perspectives
on regulation of the apoptosis induced by 
the PKCα inhibitor Gö 6976 and the 
ERK inhibitor PD98059. Figure 6 shows 
that both Gö 6976 (1 μM) and PD98059 
(20 μM) were able to induce apoptosis, espe-
cially in MCF-7 and CHO cells (p < 0.05). 
Specifically, the apoptosis rate induced by 
Gö 6976 was higher than that induced by 
PD98059. In contrast, the apoptosis rate 
was reduced by PBDE-209 treatment in 
MCF-7 and MCF-7/ADR cells compared 
with vehicle controls (0 nM PBDE-209; 
p < 0.05), but it was not reduced in HeLa, 
CHO, or OVCAR-3 cells. Moreover, in all 
cells, 100 nM PBDE-209 reduced Gö 6976-
induced apoptosis more than did 50 nM 
PBDE-209 (Figure 6). However, only 
100 nM PBDE-209 reduced PD98059-
induced apoptosis in MCF-7 cells and CHO 
cells (Figure 6).
Discussion
PBDEs are structurally similar to other 
environ  mental contaminants, such as poly-
chlorinated biphenyls and organochlorines, 
which are potential carcinogens according 
to reports from the International Agency for 
Research on Cancer (1978, 1991). Thus, 
PBDEs may have similar properties, such as 
environ  mental persistence and lipophilicity, 
that might be able to induce intra  cellular and 
Figure 4. Effect of PBDE‑209 on regulation of tamoxifen‑induced apoptosis in MCF‑7 (A,B) and MCF‑7/ADR (C,D) breast cancer cells. Cells were grown, starved 
overnight without serum, treated with different doses of PBDE‑209 (PBDE) with or without 5 μM tamoxifen for 72 hr in medium containing 1% serum, and then sub‑
jected to flow cytometry. Cells treated with 0.1% DMSO were used as vehicle control (VC). Abbreviations: B50, 50 nM PBDE‑209; B100, 100 nM PBDE‑209; T5, 5 μM 
tamoxifen; T5B50, 5 μM tamoxi  fen + 50 nM PBDE‑209; T5B100, 5 μM tamoxi  fen + 100 nM PBDE‑209. Histograms (A,C) present flow cytometric data, and the bar 
charts (B,D) present percentages of apoptosis. The experiments were performed three times, and the data shown in B and D are mean ± SD of three values. 
*p < 0.05 versus VC. **p < 0.05 versus tamoxifen alone. #p < 0.01 versus tamoxifen alone. 
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organism toxicity (Birnbaum and Staskal 
2004; Helleday et al. 1999). However, inves-
tigation into the toxicity and carcinogenicity 
of PBDE-209 in humans remains surprisingly 
limited and uncertain. In the present study, 
we demonstrate that PBDE-209 induces pro-
liferation of breast, cervi  cal, and ovarian can-
cer cells and normal ovarian CHO cells in a 
dose-dependent manner. However, our data 
contradict data from Hu et al. (2007), which 
showed that PBDE-209 inhibited hepatoma 
cell viability in a time- and concentration-
dependent fashion at doses between 10 and 
100 μM. The difference between the two 
studies may be because the doses they used 
were 100–1,000 times higher than those we 
used, and doses that high may not be achiev-
able in humans through environmental expo-
sure. Moreover, in our study PBDE-209 
antagonized Gö 6976- and PD98059-induced 
apoptosis in cancer cells and partially antago-
nized tamoxifen-induced breast cancer cell 
apoptosis. However, it remains unknown 
whether this is related to the fact that some 
advanced breast cancers initially respond well 
to tamoxifen but eventually become resistant 
to it. Whether PBDE-209 affects cervical and 
ovarian cancer treatment needs to be con-
firmed using clinical data, for example, data 
from areas where PBDE is highly used [e.g., 
Zhejiang province of China, where morbidity 
from lung, kidney, and liver cancer is higher 
(Zhao et al. 2009)]. 
Furthermore, PBDEs can also elicit 
thyroidogenic-like and estrogen-like activ-
ity in vitro (Meerts et al. 2000). Thus, we 
chose ER-positive breast cancer cells (MCF-7) 
and ER-negative breast cancer cells (MCF-7/
ADR) (Kalantzi et al. 2004) to assess the 
effect of PBDE-209 in this study. We used 
phenol red–free growth medium and DCC-
FBS to eliminate the effects of estrogen in 
the cells and found that 100 nM PBDE-209 
could induce cell prolifera  tion 1.77-fold 
greater in MCF-7 cells than in MCF-7/ADR 
cells, but estrogen could not be detected in 
the culture medium of either of these breast 
cancer cells after 100 nM PBDE-209 expo-
sure for 7 days (data not shown). Data from 
the present study indicate that PBDE-209 
has multiple toxic functions in these cells, 
perhaps not through the ER pathway, because 
PBDE-209 can induce cell proliferation in 
both ER-positive and ER-negative cells. 
PKCα is one of 12 members of the PKC 
family, which are serine/threonine kinases 
involved in many important cellular func-
tions, such as cell proliferation, migration, 
differentiation, and apoptosis (Clemens et al. 
1992; Hug and Sarre 1993; Tanaka et al. 
2003). Mitogen-activated protein kinases 
include four different types of proteins, 
that is, ERK1/2, c-jun N-terminal kinase/
stress-activated protein kinase (JNK/SAPK), 
Figure 5. Evaluation of PKCα and ERK1/2 phosphorylation (P) in cells shown by Western blotting. Cells were 
grown, starved for 24 hr without serum, and treated with different doses of PBDE‑209 (up to 100 nM) for 15 min 
in medium containing 1% serum (A), or treated with 50 nM PBDE‑209 for up to 120 min (B). Cells were then sub‑
jected to Western blotting. Cells treated with 0.1% DMSO were used as vehicle control (VC). The experiments 
were repeated twice, with similar data for both experiments. β‑Actin was used as a loading control. 
MCF-7/ADR
PBDE-209 (nM) VC 51 52 55 0 100 VC 51 52 55 0 100 Time (min)
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Figure 6. Effects of PBDE‑209 on regulation of apoptosis induced by the PKCα inhibitor Gö 6976 or the ERK 
inhibitor PD98059. Cells were pretreated with 1 μM Gö 6976 (Gö) or 20 μM PD98059 (PD) for 30 min and then 
treated with 0, 50, or 100 nM PBDE‑209 for 72 hr. Cells treated with 0.1% DMSO were used as the vehicle 
control (VC; 0 nM PBDE‑209). Data shown are mean ± SD of three experiments. 
*p < 0.05 versus VC. **p < 0.05 versus Gö 6976 or PD98059 treatment alone.
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big MAP kinase 1 (BMK1 or ERK5), and 
the p38 group of protein kinases (Zarubin 
and Han 2005), which are serine/threonine 
protein kinases that are activated by diverse 
stimuli, including cyto  kines, growth factors, 
neuro  transmitters, hormones, cellular stress, 
or cell adherence. Activation of PKCα/ERK 
proteins has been reported to promote cell 
proliferation (Fujii et al. 2005) but inhibit 
apoptosis (Tian et al. 2009). Data from the 
present study show that PBDE-209 induced 
phosphorylation of PKCα and ERK1/2 pro-
teins in both MCF-7 and MCF-7/ADR cells. 
Our finding is similar to that of Mercado-
Feliciano and Bigsby (2008), who showed 
that PBDE-209 induced cell proliferation in 
MCF-7 cells, but induction was blocked by 
anti  estrogen treatment. 
Previous studies revealed that PBDE bio-
accumulates in the ovary and changes its struc-
ture (Darnerud and Risberg 2006; Talsness 
et al. 2008). However, the role of PBDE in the 
ovary remains unknown. In the present study, 
we showed that PBDE-209 promotes growth 
of CHO (normal ovary) cells and OVCAR-3 
ovarian cancer cells. PBDE-induced CHO cell 
proliferation was mediated through induction 
of the S phase of the cell cycle, whereas PBDE-
increased OVCAR-3 cell growth was medi-
ated through an elevation of the G2/M phase. 
However, the differential effect of PBDE on 
normal and cancerous ovarian cells remains to 
be determined.
Conclusion
PBDE-209 (up to 100 nM) induced not only 
proliferative effects but also anti  apoptotic 
effects in different cancer cell lines and acti-
vated PKCα and ERK1/2 phosphorylation. 
It also antagonized apoptosis induced by 
the PKCα inhibitor Gö 6976 and the ERK 
inhibitor PD98059 in these cells and partially 
antagonized tamoxifen-induced breast can-
cer cell apoptosis. Further study is needed to 
determine whether PBDE exposure is associ-
ated with cancer development in the female 
reproductive system, but avoiding exposure to 
PBDE-209 is a reasonable precaution. 
co r r e c t i o n
In the original manuscript published online, 
Fukang Xie was inadvertently omitted from 
the author list. It has been corrected here. 
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